Related Experiment Video
Updated: Jan 16, 2026
Quantitative High-throughput Single-cell Cytotoxicity Assay For T Cells
Published on: February 2, 2013
A Tissue Factor Bi-Specific T-Cell Engager Provides Effective Targeting and Cytotoxicity Against Cervical Cancer Cell
Kyung-Jun Lee1, Gilhyang Kim2,3, Booseong Seo4
1Institute of New Frontier Research Team, Hallym University, Chuncheon 24252, Republic of Korea.
Abstract:
Tissue factor (TF), also known as CD142, is a 47 kDa transmembrane glycoprotein belonging to the class II cytokine receptors superfamily. High expression of TF has been reported to be correlated with poor prognosis in various cancers. In this study, we aimed to clarify the cytotoxicity of bi-specific T-cell engagers (BiTE) targeting TF on cervical cancer cell lines. We designed and characterized the novel humanized BiTE targeting TF using an anti-human CD3 single-chain variable fragment (scFv) linked to human TF scFv. TF-Bite replication and potency were assessed in cervical cancer cell lines. The expression of the TF-BiTE and the activation and proliferation of T cells induced along with the T-cell-mediated cytotoxicity were evaluated by flow cytometry in vitro. TF expression was confirmed in SiHa, ME-180, and HeLa cell lines. The TF-BiTE showed potent TF-specific cytotoxicity and induced T-cell activation, proliferation, degranulation, and cytokine release. These effects were not observed in TF-negative control cells. Our findings support TF-BiTE as a promising therapeutic candidate for cervical cancer immunotherapy.
Insights
A novel bi-specific T-cell engager (BiTE) targeting Tissue Factor (TF) demonstrates potent cytotoxicity against cervical cancer cells. This TF-BiTE therapy effectively activates T cells, showing promise for cervical cancer immunotherapy.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Tissue Factor (TF), a transmembrane glycoprotein, is highly expressed in various cancers, correlating with poor prognosis.
- TF's role in cancer progression necessitates novel therapeutic strategies for improved patient outcomes.
Purpose of the Study:
- To evaluate the cytotoxicity of a novel bi-specific T-cell engager (BiTE) targeting Tissue Factor (TF) in cervical cancer cell lines.
- To characterize the T-cell activation and mediated cytotoxicity induced by the TF-BiTE.
Main Methods:
- Design and characterization of a humanized BiTE utilizing anti-CD3 and anti-TF single-chain variable fragments (scFvs).
- Assessment of TF-BiTE potency and replication in cervical cancer cell lines (SiHa, ME-180, HeLa).
- Evaluation of T-cell activation, proliferation, degranulation, and cytokine release via flow cytometry in vitro.
Main Results:
- TF expression was confirmed in SiHa, ME-180, and HeLa cervical cancer cell lines.
- The TF-BiTE exhibited potent TF-specific cytotoxicity and effectively induced T-cell activation, proliferation, degranulation, and cytokine release.
- These therapeutic effects were specific to TF-expressing cells, with no observed effects in TF-negative controls.
Conclusions:
- The developed TF-BiTE demonstrates significant anti-cancer activity against cervical cancer cells.
- TF-BiTE therapy holds promise as a potential immunotherapeutic agent for cervical cancer treatment.
- Further investigation into TF-BiTE as a therapeutic candidate for cervical cancer immunotherapy is warranted.
Related Concept Videos
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
01:27Tumor Immunotherapy